Financhill
Sell
12

IVA Quote, Financials, Valuation and Earnings

Last price:
$3.12
Seasonality move :
-25.26%
Day range:
$3.00 - $3.12
52-week range:
$1.53 - $4.05
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
18.87x
P/B ratio:
--
Volume:
4.7K
Avg. volume:
16.2K
1-year change:
-13.65%
Market cap:
$296M
Revenue:
$10M
EPS (TTM):
-$2.22

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
IVA
Inventiva SA
$10M -$0.29 -- -- $10.88
CLLS
Cellectis SA
$8.5M -- 36.24% -100% $5.60
DBVT
DBV Technologies SA
$630.8K -$0.30 -- -87.94% $18.41
GNFT
Genfit SA
$4M -- -- -- $8.70
IPHA
Innate Pharma SA
-- -- -- -- $7.86
NBTX
Nanobiotix SA
-- -- -- -- $7.36
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
IVA
Inventiva SA
$3.09 $10.88 $296M -- $0.00 0% 18.87x
CLLS
Cellectis SA
$1.47 $5.60 $147.4M -- $0.00 0% 3.01x
DBVT
DBV Technologies SA
$8.41 $18.41 $230M -- $0.00 0% --
GNFT
Genfit SA
$4.23 $8.70 $211.5M 32.57x $0.00 0% 2.93x
IPHA
Innate Pharma SA
$2.16 $7.86 $199.1M -- $0.00 0% 12.93x
NBTX
Nanobiotix SA
$3.66 $7.36 $173.4M -- $0.00 0% 3.98x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
IVA
Inventiva SA
-145.15% -0.481 32.05% 0.43x
CLLS
Cellectis SA
30.41% 0.907 56.64% 1.64x
DBVT
DBV Technologies SA
-- -3.919 -- --
GNFT
Genfit SA
-- 0.519 -- --
IPHA
Innate Pharma SA
55.22% -0.722 24.23% 2.76x
NBTX
Nanobiotix SA
195.9% 0.273 20.12% 1.38x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
IVA
Inventiva SA
-- -- -- -- -- --
CLLS
Cellectis SA
$8.6M -$14.2M -35.55% -49.15% -152.19% -$17.6M
DBVT
DBV Technologies SA
-- -$26.6M -- -- -- -$19.7M
GNFT
Genfit SA
-- -- -- -- -- --
IPHA
Innate Pharma SA
-- -- -39.78% -72.79% -- --
NBTX
Nanobiotix SA
-- -- -161.14% -- -- --

Inventiva SA vs. Competitors

  • Which has Higher Returns IVA or CLLS?

    Cellectis SA has a net margin of -- compared to Inventiva SA's net margin of -170.14%. Inventiva SA's return on equity of -- beat Cellectis SA's return on equity of -49.15%.

    Company Gross Margin Earnings Per Share Invested Capital
    IVA
    Inventiva SA
    -- -- -$34.6M
    CLLS
    Cellectis SA
    81.09% -$0.18 $167M
  • What do Analysts Say About IVA or CLLS?

    Inventiva SA has a consensus price target of $10.88, signalling upside risk potential of 251.72%. On the other hand Cellectis SA has an analysts' consensus of $5.60 which suggests that it could grow by 280.95%. Given that Cellectis SA has higher upside potential than Inventiva SA, analysts believe Cellectis SA is more attractive than Inventiva SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    IVA
    Inventiva SA
    6 1 0
    CLLS
    Cellectis SA
    2 1 0
  • Is IVA or CLLS More Risky?

    Inventiva SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Cellectis SA has a beta of 3.107, suggesting its more volatile than the S&P 500 by 210.711%.

  • Which is a Better Dividend Stock IVA or CLLS?

    Inventiva SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inventiva SA pays -- of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IVA or CLLS?

    Inventiva SA quarterly revenues are --, which are smaller than Cellectis SA quarterly revenues of $10.7M. Inventiva SA's net income of -- is lower than Cellectis SA's net income of -$18.1M. Notably, Inventiva SA's price-to-earnings ratio is -- while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inventiva SA is 18.87x versus 3.01x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IVA
    Inventiva SA
    18.87x -- -- --
    CLLS
    Cellectis SA
    3.01x -- $10.7M -$18.1M
  • Which has Higher Returns IVA or DBVT?

    DBV Technologies SA has a net margin of -- compared to Inventiva SA's net margin of --. Inventiva SA's return on equity of -- beat DBV Technologies SA's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    IVA
    Inventiva SA
    -- -- -$34.6M
    DBVT
    DBV Technologies SA
    -- -$1.30 --
  • What do Analysts Say About IVA or DBVT?

    Inventiva SA has a consensus price target of $10.88, signalling upside risk potential of 251.72%. On the other hand DBV Technologies SA has an analysts' consensus of $18.41 which suggests that it could grow by 118.9%. Given that Inventiva SA has higher upside potential than DBV Technologies SA, analysts believe Inventiva SA is more attractive than DBV Technologies SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    IVA
    Inventiva SA
    6 1 0
    DBVT
    DBV Technologies SA
    0 0 0
  • Is IVA or DBVT More Risky?

    Inventiva SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.661, suggesting its less volatile than the S&P 500 by 166.125%.

  • Which is a Better Dividend Stock IVA or DBVT?

    Inventiva SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inventiva SA pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IVA or DBVT?

    Inventiva SA quarterly revenues are --, which are smaller than DBV Technologies SA quarterly revenues of --. Inventiva SA's net income of -- is lower than DBV Technologies SA's net income of -$27.1M. Notably, Inventiva SA's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inventiva SA is 18.87x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IVA
    Inventiva SA
    18.87x -- -- --
    DBVT
    DBV Technologies SA
    -- -- -- -$27.1M
  • Which has Higher Returns IVA or GNFT?

    Genfit SA has a net margin of -- compared to Inventiva SA's net margin of --. Inventiva SA's return on equity of -- beat Genfit SA's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    IVA
    Inventiva SA
    -- -- -$34.6M
    GNFT
    Genfit SA
    -- -- --
  • What do Analysts Say About IVA or GNFT?

    Inventiva SA has a consensus price target of $10.88, signalling upside risk potential of 251.72%. On the other hand Genfit SA has an analysts' consensus of $8.70 which suggests that it could grow by 105.73%. Given that Inventiva SA has higher upside potential than Genfit SA, analysts believe Inventiva SA is more attractive than Genfit SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    IVA
    Inventiva SA
    6 1 0
    GNFT
    Genfit SA
    1 0 0
  • Is IVA or GNFT More Risky?

    Inventiva SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Genfit SA has a beta of 0.919, suggesting its less volatile than the S&P 500 by 8.105%.

  • Which is a Better Dividend Stock IVA or GNFT?

    Inventiva SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Genfit SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inventiva SA pays -- of its earnings as a dividend. Genfit SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IVA or GNFT?

    Inventiva SA quarterly revenues are --, which are smaller than Genfit SA quarterly revenues of --. Inventiva SA's net income of -- is lower than Genfit SA's net income of --. Notably, Inventiva SA's price-to-earnings ratio is -- while Genfit SA's PE ratio is 32.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inventiva SA is 18.87x versus 2.93x for Genfit SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IVA
    Inventiva SA
    18.87x -- -- --
    GNFT
    Genfit SA
    2.93x 32.57x -- --
  • Which has Higher Returns IVA or IPHA?

    Innate Pharma SA has a net margin of -- compared to Inventiva SA's net margin of --. Inventiva SA's return on equity of -- beat Innate Pharma SA's return on equity of -72.79%.

    Company Gross Margin Earnings Per Share Invested Capital
    IVA
    Inventiva SA
    -- -- -$34.6M
    IPHA
    Innate Pharma SA
    -- -- $68.9M
  • What do Analysts Say About IVA or IPHA?

    Inventiva SA has a consensus price target of $10.88, signalling upside risk potential of 251.72%. On the other hand Innate Pharma SA has an analysts' consensus of $7.86 which suggests that it could grow by 263.74%. Given that Innate Pharma SA has higher upside potential than Inventiva SA, analysts believe Innate Pharma SA is more attractive than Inventiva SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    IVA
    Inventiva SA
    6 1 0
    IPHA
    Innate Pharma SA
    1 1 0
  • Is IVA or IPHA More Risky?

    Inventiva SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Innate Pharma SA has a beta of 0.197, suggesting its less volatile than the S&P 500 by 80.329%.

  • Which is a Better Dividend Stock IVA or IPHA?

    Inventiva SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Innate Pharma SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inventiva SA pays -- of its earnings as a dividend. Innate Pharma SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IVA or IPHA?

    Inventiva SA quarterly revenues are --, which are smaller than Innate Pharma SA quarterly revenues of --. Inventiva SA's net income of -- is lower than Innate Pharma SA's net income of --. Notably, Inventiva SA's price-to-earnings ratio is -- while Innate Pharma SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inventiva SA is 18.87x versus 12.93x for Innate Pharma SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IVA
    Inventiva SA
    18.87x -- -- --
    IPHA
    Innate Pharma SA
    12.93x -- -- --
  • Which has Higher Returns IVA or NBTX?

    Nanobiotix SA has a net margin of -- compared to Inventiva SA's net margin of --. Inventiva SA's return on equity of -- beat Nanobiotix SA's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    IVA
    Inventiva SA
    -- -- -$34.6M
    NBTX
    Nanobiotix SA
    -- -- $24.3M
  • What do Analysts Say About IVA or NBTX?

    Inventiva SA has a consensus price target of $10.88, signalling upside risk potential of 251.72%. On the other hand Nanobiotix SA has an analysts' consensus of $7.36 which suggests that it could grow by 101.19%. Given that Inventiva SA has higher upside potential than Nanobiotix SA, analysts believe Inventiva SA is more attractive than Nanobiotix SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    IVA
    Inventiva SA
    6 1 0
    NBTX
    Nanobiotix SA
    3 1 0
  • Is IVA or NBTX More Risky?

    Inventiva SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nanobiotix SA has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock IVA or NBTX?

    Inventiva SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanobiotix SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inventiva SA pays -- of its earnings as a dividend. Nanobiotix SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IVA or NBTX?

    Inventiva SA quarterly revenues are --, which are smaller than Nanobiotix SA quarterly revenues of --. Inventiva SA's net income of -- is lower than Nanobiotix SA's net income of --. Notably, Inventiva SA's price-to-earnings ratio is -- while Nanobiotix SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inventiva SA is 18.87x versus 3.98x for Nanobiotix SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IVA
    Inventiva SA
    18.87x -- -- --
    NBTX
    Nanobiotix SA
    3.98x -- -- --

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Cisco Stock Forecast: Is It Ready to Surprise Us?
Cisco Stock Forecast: Is It Ready to Surprise Us?

Let’s be real Cisco Systems (NASDAQ: CSCO) hasn’t exactly been…

Where Will Gartner Stock Be in 5 Years?
Where Will Gartner Stock Be in 5 Years?

If you’ve ever wondered what it’s like to invest in…

Rambus (RMBS) Stock Forecast, Can the Rally Continue in 2025?
Rambus (RMBS) Stock Forecast, Can the Rally Continue in 2025?

Rambus has flown under the radar, but the numbers tell…

Stock Ideas

Buy
65
Is MSFT Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 38x

Buy
65
Is NVDA Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 45x

Sell
33
Is AAPL Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 32x

Alerts

Buy
60
MRUS alert for May 24

Merus NV [MRUS] is up 32.55% over the past day.

Buy
57
RGC alert for May 24

Regencell Bioscience Holdings [RGC] is up 28.43% over the past day.

Buy
90
OKLO alert for May 24

Oklo [OKLO] is up 23.11% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock